EA201791154A1 - Лечение болезней и нарушений аналогами кальцитонина - Google Patents

Лечение болезней и нарушений аналогами кальцитонина

Info

Publication number
EA201791154A1
EA201791154A1 EA201791154A EA201791154A EA201791154A1 EA 201791154 A1 EA201791154 A1 EA 201791154A1 EA 201791154 A EA201791154 A EA 201791154A EA 201791154 A EA201791154 A EA 201791154A EA 201791154 A1 EA201791154 A1 EA 201791154A1
Authority
EA
Eurasian Patent Office
Prior art keywords
violations
diseases
treatment
calcitonin analogues
calcitonin
Prior art date
Application number
EA201791154A
Other languages
English (en)
Inventor
Мортен Карсдаль
Ким Хенриксен
Ким Виц Андреассен
Софи Гюдесен
Сара Тофтегард Хюлер
Original Assignee
Кибайосайнс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кибайосайнс Аг filed Critical Кибайосайнс Аг
Publication of EA201791154A1 publication Critical patent/EA201791154A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Аналоги кальцитонинов в качестве лекарственного средства для снижения триглицеридов в печени или для уменьшения накопления жира в печени субъекта.
EA201791154A 2015-01-08 2016-01-07 Лечение болезней и нарушений аналогами кальцитонина EA201791154A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1500263.7A GB201500263D0 (en) 2015-01-08 2015-01-08 Calcitonin analogues for treating diseases and disorders
PCT/EP2016/050186 WO2016110525A1 (en) 2015-01-08 2016-01-07 Calcitonin analogues for treating diseases and disorders

Publications (1)

Publication Number Publication Date
EA201791154A1 true EA201791154A1 (ru) 2017-09-29

Family

ID=52597359

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791154A EA201791154A1 (ru) 2015-01-08 2016-01-07 Лечение болезней и нарушений аналогами кальцитонина

Country Status (17)

Country Link
US (2) US10350272B2 (ru)
EP (1) EP3247383A1 (ru)
JP (1) JP2018502854A (ru)
KR (1) KR20170120576A (ru)
CN (1) CN107206056A (ru)
AU (1) AU2016205994A1 (ru)
BR (1) BR112017014552A2 (ru)
CA (1) CA2969293A1 (ru)
CL (1) CL2017001773A1 (ru)
CO (1) CO2017007007A2 (ru)
EA (1) EA201791154A1 (ru)
GB (1) GB201500263D0 (ru)
IL (1) IL253026A0 (ru)
MX (1) MX2017008755A (ru)
PE (1) PE20171320A1 (ru)
PH (1) PH12017500988A1 (ru)
WO (1) WO2016110525A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201704429D0 (en) * 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) * 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1329502A (zh) 1998-12-04 2002-01-02 普罗瓦利斯英国有限公司 含有胰岛素的药物组合物
AU4216700A (en) 1999-04-05 2000-10-23 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP2359817B1 (en) 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
TWI343816B (en) 2003-07-23 2011-06-21 Novartis Ag Use of calcitonin in osteoarthritis
WO2005094785A2 (en) 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
AU2005263729B2 (en) 2004-07-22 2011-01-06 Bey Pharma GmbH Use of compounds containing thiol groups as an efflux pump inhibitor
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
WO2007002532A2 (en) 2005-06-24 2007-01-04 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
CA2621577C (en) 2005-09-06 2013-12-24 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
PL1834635T3 (pl) 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
WO2007117706A2 (en) 2006-04-07 2007-10-18 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
AU2010206614B2 (en) * 2009-01-22 2015-03-26 Keybioscience Ag Treatment for obesity
US9006172B2 (en) 2011-11-02 2015-04-14 Keybioscience Ag Peptide analogs for treating diseases and disorders
MX2016006049A (es) * 2013-11-14 2016-08-12 Keybioscience Ag Mimeticos de calcitonina para tratar enfermedades y trastornos.

Also Published As

Publication number Publication date
PH12017500988A1 (en) 2017-12-18
IL253026A0 (en) 2017-08-31
US10350272B2 (en) 2019-07-16
EP3247383A1 (en) 2017-11-29
CN107206056A (zh) 2017-09-26
KR20170120576A (ko) 2017-10-31
US20190328843A1 (en) 2019-10-31
CL2017001773A1 (es) 2018-03-09
AU2016205994A1 (en) 2017-06-15
GB201500263D0 (en) 2015-02-25
BR112017014552A2 (pt) 2018-05-15
CA2969293A1 (en) 2016-07-14
PE20171320A1 (es) 2017-09-07
CO2017007007A2 (es) 2018-01-31
WO2016110525A1 (en) 2016-07-14
MX2017008755A (es) 2017-11-17
JP2018502854A (ja) 2018-02-01
US20180264085A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
IL264025A (en) Novel fatty acid-modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
EA201691582A1 (ru) Новые фармацевтические препараты
EP3349783C0 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH THE TREATMENT OF DISEASES
DK3273942T3 (da) Mikronåleplaster til indgivelse af en aktiv bestanddel til huden
EA201590058A1 (ru) Аналоги глюкагона
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201691911A1 (ru) Быстродействующие композиции инсулина
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201991484A1 (ru) Лекарственные формы энзалутамида
DK2844279T3 (da) Doseringsprogrammer til behandling af pompes sygdom
EA201791617A1 (ru) Аналоги амилина
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
ZA201900921B (en) Administration of substances to animals
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201791154A1 (ru) Лечение болезней и нарушений аналогами кальцитонина
DK3500586T3 (da) Kontinuerlig fremgangsmåde til at reducere heterogenitet af terapeutisk protein
BR112017007860A2 (pt) método para tratar uma doença de gordura no fígado
EP3318261A4 (en) Use of zoledronic acid to prepare drug treating fatty liver disease
EA201691130A8 (ru) Средства и способы противодействия миелопролиферативным или лимфопролиферативным расстройствам
EA201791657A1 (ru) Модуляторы аденозиновых рецепторов a
MA41782A (fr) Traitement de patients atteints de diabète de type 2
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose